Biomedical Research Education & Training
Faculty Member

Dave, Utpal P., M.D.
Assistant Professor of Medicine

Lab Url: N/A

Phone Number: 615-322-4967

Email Address: utpal.dave@vanderbilt.edu

Dave, Utpal's picture
Academic history
B.S., Northwestern University
M.D., Northwestern University
postdoc, Univ of Texas Soutwestern Med Ctr
postdoc, National Cancer Institute

Office Address   Mailing Address

552 PRB

Division of Hematology/Oncology Vanderbilt University Medical Center, 777 PRB 37232-6307


Research Specialty
Molecular genetics of leukemia and lymphoma

Research Description
My lab is interested in the oncogenic pathways that are deregulated in human T-cell neoplasms. These cancers can be divided based on the cell of origin into immature, T-cell acute lymphoblastic leukemias (T-ALL) and mature, peripheral T-cell Non-Hodgkin lymphomas. In T-ALL, we are focused on understanding the function of the LIM-domain-Only-2 (LMO2) gene which is deregulated in the majority of patients. Mouse knockout studies show that Lmo2 is required for the maintenance of the hematopoietic stem cells. We hypothesize that the pathways Lmo2 regulates in stem cells may also be induced in Lmo2-associated leukemias. Experiments are ongoing to explore this idea.


Our other projects address the mechanism of mature T-cell transformation by studying HTLV-1-induced disease. HTLV-1 is a complex retrovirus that induces leukemia or lymphoma in only 5% of infected carriers after a long latency of 30-50 years. This long latency in the setting of lifelong viremia is reminiscent of the slow transforming murine leukemia viruses that we are studying in mice. Likewise, we hypothesize that insertional mutagenesis may be an active mechanism of disease induction for HTLV-1. Another project involves the role of the IL-2/IL2RG pathway in leukemia induction. We hypothesize that gain of function mutations may be occurring in genes in this pathway as tumor progression events.

Our studies will shed light on the pathogenesis of T-cell neoplasms and may provide novel targets for diagnosis or therapy.







Publications
Smith, S, Tripathi, R, Goodings, C, Cleveland, S, Mathias, E, Hardaway, JA, Elliott, N, Yi, Y, Chen, X, Downing, J, Mullighan, C, Swing, DA, Tessarollo, L, Li, L, Love, P, Jenkins, NA, Copeland, NG, Thompson, MA, Du, Y, Dav??, UP. LIM Domain Only-2 (LMO2) Induces T-Cell Leukemia by Two Distinct Pathways. PLoS One, 9(1), e85883, 2014

Cleveland, SM, Smith, S, Tripathi, R, Mathias, EM, Goodings, C, Elliott, N, Peng, D, El-Rifai, W, Yi, D, Chen, X, Li, L, Mullighan, C, Downing, JR, Love, P, Dav??, UP. Lmo2 induces Hematopoietic Stem Cell like Features in T-cell Progenitor Cells Prior to Leukemia. Stem Cells, 2013

Chmielecki, J, Peifer, M, Viale, A, Hutchinson, K, Giltnane, J, Socci, ND, Hollis, CJ, Dean, RS, Yenamandra, A, Jagasia, M, Kim, AS, Dav??, UP, Thomas, RK, Pao, W. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes Chromosomes Cancer, 51(1), 54-65, 2012

Subramaniam, PS, Whye, DW, Efimenko, E, Chen, J, Tosello, V, De Keersmaecker, K, Kashishian, A, Thompson, MA, Castillo, M, Cordon-Cardo, C, Dav??, UP, Ferrando, A, Lannutti, BJ, Diacovo, TG. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell, 21(4), 459-72, 2012

Aue, G, Du, Y, Cleveland, SM, Smith, SB, Dav??, UP, Liu, D, Weniger, MA, Metais, JY, Jenkins, NA, Copeland, NG, Dunbar, CE. Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia. Blood, 118(17), 4674-81, 2011

Elliott, NE, Cleveland, SM, Grann, V, Janik, J, Waldmann, TA, Dav??, UP. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood, 118(14), 3911-21, 2011 PMCID:3193267

Biswas, S, Shi, Q, Matise, L, Cleveland, S, Dave, U, Zinkel, S. A role for proapoptotic Bax and Bak in T-cell differentiation and transformation. Blood, 116(24), 5237-46, 2010 PMCID:3012541

Dave, UP, Akagi, K, Tripathi, R, Cleveland, SM, Thompson, MA, Yi, M, Stephens, R, Downing, JR, Jenkins, NA, Copeland, NG. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet, 5(5), e1000491, 2009 PMCID:2679194

Dave, UP. Leukemia takes center (late) stage. Blood, 112(6), 2175-6, 2008

Dave, Utpal P.. RIS defines risk. Blood, 110, 1704, 2007

Dave, UP, Jenkins, NA, Copeland, NG. Gene therapy insertional mutagenesis insights. Science, 303(5656), 333, 2004

Ye, J, Dave, UP, Grishin, NV, Goldstein, JL, Brown, MS. Asparagine-proline sequence within membrane-spanning segment of SREBP triggers intramembrane cleavage by site-2 protease. Proc Natl Acad Sci U S A, 97(10), 5123-8, 2000 PMCID:25792

Ye, J, Rawson, RB, Komuro, R, Chen, X, Dave, UP, Prywes, R, Brown, MS, Goldstein, JL. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell, 6(6), 1355-64, 2000

Duncan, EA, Dave, UP, Sakai, J, Goldstein, JL, Brown, MS. Second-site cleavage in sterol regulatory element-binding protein occurs at transmembrane junction as determined by cysteine panning. J Biol Chem, 273(28), 17801-9, 1998


Postdoctoral Position Available
No

Postdoctoral Position Details
N/A

Updated Date
01/30/2014